A Study to Investigate the Effects of Zibotentan/Dapagliflozin Combination Compared to Dapagliflozin Alone in Adult Participants With Chronic Kidney Disease and High Proteinuria

Inclusion Criteria: * ≥ 18 years of age at the time of signing the informed consent. * Diagnosis of CKD with eGFR ≥ 20 and \< 90 mL/min/1.73m2 AND UACR \> 700 mg/g (\> 79 mg/mmol) or UPCR \> 1000 mg/g (\> 113 mg/mmol). * Body mass index (BMI) within the range ≤40 kg/m2. * Female participants must be either - not of child-bearing potential or - women of childbearing potential (WOCBP) using at least one highly effective birth control method for at least 3 months prior to first dose of study intervention. * All WOCBP must have a negative serum pregnancy test result at screening. * Receiving RAASi therapy (ACEi or ARB), and for the patient maximum tolerated labelled daily dose, that has been stable for at least 4 weeks. Exclusion Criteria: * Clinically significant, unstable, or uncontrolled medical condition which in the Investigator's opinion makes it undesirable for the participant to participate in the study. * Known hypersensitivity to dapagliflozin or zibotentan or any of the excipients of the investigational product. History or ongoing allergy/hypersensitivity, as judged by the investigator, to SGLT2i therapy or ERAs. * NYHA class III or class IV HF. * Participants hospitalised for HF and/or who have not been stable on HF therapy during the last 6 months prior to screening. * HF due to cardiomyopathies that would primarily require other specific treatment. * High output HF (eg, due to hyperthyroidism or Paget's disease). * HF due to primary cardiac valvular disease/dysfu…